替普瑞酮治疗幽门螺杆菌阴性萎缩性胃炎的疗效评价

目的探析幽门螺杆菌(Hp)阴性萎缩性胃炎患者应用替普瑞酮治疗的临床效果。方法对2016年5月—2018年4月在我院接受治疗的108例Hp阴性萎缩性胃炎患者进行研究,根据随机抽签法分为两组,即对照组(n=54)、观察组(n=54)。对照组患者应用胶体果胶铋胶囊治疗,观察组患者应用替普瑞酮治疗,对两组患者临床疗效、胃黏膜病变程度、症状积分及不良反应发生率进行统计比较。结果观察组患者临床总有效率(94.44%)高于对照组患者(81.48%),差异有统计学意义(P <0.05)。观察组患者胃黏膜病变程度评分低于对照组患者,差异有统计学意义(P <0.05)。观察组患者治疗后症状积分低于对照组患者,差异有统计学意义(P <0.05)。观察组患者不良反应发生率(3.7%)低于对照组患者(14.8%),差异有统计学意义(P <0.05)。结论 Hp阴性萎缩性胃炎患者应用替普瑞酮治疗的临床效果更加显著,不仅可以减轻胃黏膜病变程度,改善临床症状,还可以减少不良反应的发生。

The observation of single-agent gemcitabine maintenance therapy in patients with metastatic breast cancer

Objective:The aim of the study was to evaluate the efficacy and tolerability of single-agent gemcitabine in the maintenance treatment of histologically confirmed metastatic breast cancer cases.Methods:The 45 patients carried efficacious chemotherapy were divided into maintenance therapy group(n=23) and control group(n=22) according to the different treatment methods.Patients in the maintenance therapy group received gemcitabine therapy until 6 cycles,disease progression or adverse effect intolerance.Within the control group,the patients were given best supportive care.Follow-up was made until disease progression,death or 2 years.The short-term clinical efficacy and adverse effects,progression-free survival(PFS) and median survival of recurrence(MSR) of these two groups were compared and analyzed.Results:Compared with the control group,the experiment group had higher response rate(RR;73.9% vs 31.8%;P<0.05),and significantly progress of median PFS(13.1 vs 9.6 months;P<0.05).However,the progression of MSR had no statistically difference with the control group(23.3 vs 21.1 months;P>0.05).Most of the treatment-related adverse events were mild,and the most common adverse event was hematologic toxicity.The 3 cases occurred grades 3–4 neutropenia and 3 cases occurred grades 3–4 thrombocytopenia.The 1 patient stopped treatment because of grade 3 allergic reaction,and 4 patients required dose reduction for grade 4 adverse events.Other adverse effects were grades 1–2,and all were recovered after symptomatic treatment.There was no significant side effect which threatened the life.Conclusion:In the extension maintenance treatment,gemcitabine can consolidate the therapeutic effect in advance and significantly prolong median PFS of metastatic breast cancer patients.In conclusion,gemcitabine monotherapy with a favorable safety profile is an effective maintenance treatment in metastatic breast cancer patients.

Clinical observation on docetaxel plus S1 in the treatment of advanced metastatic breast cancer

Objective: The aim of our study was to observe the efficacy and adverse reactions of docetaxel plus S1 in patients with advanced metastatic breast cancer. Methods: Twenty-seven patients with advanced metastatic breast cancer receiving docetaxel plus S1 in our hospital were analyzed. The efficacy and safety were evaluated according to RECIST and NCI CTC 3.0. Results: The clinical efficacy and toxicity were evaluated in all the 27 patients, including 1 case of CR, 12 of PR, 6 of SD, and 8 of PD (ORR = 48.1%, CBR = 70.3%). The median time to tumor progression (mTTP) was 7.3 months. No IV degree of adverse reaction was observed in the observation group. Most adverse reactions were degrees I and II, the most common reactions were neutropenia (59.3%), abnormal liver function (33.3%), gastrointestinal adverse events (29.6 %) and stomatitis (7.4%). Conclusion: With good efficacy and low toxicity, docetaxel plus S1 could be administered in the treatment of advanced metastatic breast cancer.

The clinical observation of neoadjuvant chemotherapy in locally advanced breast cancer with DX regimen

The recent clinical curative effect and adverse events of docetaxel and capecitabine （DX） of neo- adjuvant chemotherapy in patients with locally advanced breast cancer was discussed. Methods： The data of 72 cases of neoadjuvant chemotherapy （DX） in locally advanced breast cancer after 4 cycles were retrospectively analyzed. Docetaxel 75 mg/m^2 by infusion 1 h on dl, capecitabine 2000 mg/m^2 by oral for twice daily on d1-14, 21 days was a cycle. Results： All 72 patients were assessed for efficacy and adverse events. The total effective rate was 80.5% （58/72）, including pathological complete response （pCR） was 7 （9.7%）, clinical complete remission （cCR） was 15（20.8%）, clinical partial response （PR） was 43 （59.7%）, stable disease （SD） was 8 （11.1%） and progressive disease （PD） was 6 （8.3%）. The main adverse events were gastrointestinal reactions and bone marrow suppression. The 3 to 4 degrees of adverse reactions including granulocytopenia in 7 patients （20.6%）, hand-foot syndrome in 6 patients （15.2%）. Conclusion： The DX regimen provide a favorable efficacy and safety profile in patients with locally advanced breast cancer for neoadjuvant chemotherapy.

左氧氟沙星与地塞米松联合用于中耳炎的治疗效果研究

目的研究中耳炎患者行左氧氟沙星^(+)地塞米松治疗的效果。方法选择我院2020年1月-2022年12月收治的73例中耳炎患者,“随机取样法”分单一组(左氧氟沙星,n=37)、联用组(左氧氟沙星^(+)地塞米松,n=36),两组疗效比较。结果用药前分析炎症程度、T细胞亚群无差异,用药后分析不良反应无差异,P>0.05;用药后较单一组,联用组IL-2、IL-4、IL-8、TNF-a值更低:CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)值更高,CD8^(+)值更低;联用组有效率(97.30%)高于单一组(83.33%),P<0.05。结论左氧氟沙星^(+)地塞米松治疗中耳炎患者可减缓炎症程度、改善T细胞亚群,增强疗效、减少副作用发生,值得推崇。

The XIA's No. 1 Sleeping Prescription for the Treatment of Insomnia of the Deficiency Type:A Clinical Observation of 60 Cases

Objective： To evaluate the therapeutic effects and safety of the XIA＇s No.1 Sleeping Prescription for the treatment of insomnia of the deficiency type. Methods： 120 cases conformed to the diagnostic criteria of the Chinese Classification of Mental Disorders-Version 3 （CCMD-3） and were diagnosed as having insomnia of the deficiency type were divided randomly into a treatment group and a control group, 60 cases in each group. The treatment group was treated with the XIA＇s No.1 Sleeping Prescription, while the control group was given estazolam （ling） for 6 weeks. The Athens Insomnia Scale （AIS） was used to evaluate the clinical therapeutic effects, while the treatment emergent symptom scale （TESS） was used to evaluate adverse reactions. Results： The total effective rate of the treatment group （80%） was higher than that of the control group （70%）, but with no significant difference （P〉0.05）. The effective rate for long-term insomnia was 77.8% in the treatment group and 52.4% in the control group, with a significant difference between the two groups （P〈0.05）. The adverse reactions shown in the treatment group were obviously fewer and milder than those in the control group. Conclusion： The XIA＇s No. 1 Sleeping Prescription is effective for insomnia of the deficiency type and with no obvious toxic side effects.